The decision was supported by a randomised, six-week, placebo-controlled trial involving 316 adolescent subjects.
The European Commission (EC) has approved Danish CNS specialist Lundbeck (LUND: CO) and Otsuka Europe’s Rxulti ...
Otsuka Pharmaceutical Europe and Lundbeck have announced that the European Commission has approved Rxulti (brexpiprazole) for ...
Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has approved Rxulti® (brexpiprazole) for the treatment of schizophrenia in ...
Otsuka America Pharmaceutical is continuing its work to provide support to and advocate for family caregivers. | Otsuka ...
Welcome to the first edition of Changing Faces for 2025. January kicked off the year with a flurry of notable leadership ...
and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results